FI20002515A - Ihmisen C3b/C4b-reseptori (CR1) - Google Patents

Ihmisen C3b/C4b-reseptori (CR1) Download PDF

Info

Publication number
FI20002515A
FI20002515A FI20002515A FI20002515A FI20002515A FI 20002515 A FI20002515 A FI 20002515A FI 20002515 A FI20002515 A FI 20002515A FI 20002515 A FI20002515 A FI 20002515A FI 20002515 A FI20002515 A FI 20002515A
Authority
FI
Finland
Prior art keywords
fragments
expression
protein
secreted
proteins
Prior art date
Application number
FI20002515A
Other languages
English (en)
Swedish (sv)
Other versions
FI115528B (fi
Inventor
Douglas T Fearon
Lloyd B Klickstein
Winnie W Wong
Gerald R Carson
Michael F Concino
Stephen H Ip
Savvas C Makrides
Jr Henry C Marsh
Original Assignee
Univ Johns Hopkins
Brigham & Womens Hospital
Avant Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Brigham & Womens Hospital, Avant Immunotherapeutics Inc filed Critical Univ Johns Hopkins
Publication of FI20002515A publication Critical patent/FI20002515A/fi
Application granted granted Critical
Publication of FI115528B publication Critical patent/FI115528B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Joining Of Building Structures In Genera (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI20002515A 1988-04-01 2000-11-16 Menetelmä rekombinanttisen, liukoisen tyypin I komplementtireseptorimolekyylin puhdistamiseksi FI115528B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17653288A 1988-04-01 1988-04-01
US17653288 1988-04-01
US8901358 1989-03-31
PCT/US1989/001358 WO1989009220A1 (en) 1988-04-01 1989-03-31 THE HUMAN C3b/C4b RECEPTOR (CR1)
US41274589A 1989-09-26 1989-09-26
US41274589 1989-09-26

Publications (2)

Publication Number Publication Date
FI20002515A true FI20002515A (fi) 2000-11-16
FI115528B FI115528B (fi) 2005-05-31

Family

ID=26872337

Family Applications (2)

Application Number Title Priority Date Filing Date
FI904842A FI106316B (fi) 1988-04-01 1990-10-01 Ihmisen C3b/C4b-reseptori (CR1)
FI20002515A FI115528B (fi) 1988-04-01 2000-11-16 Menetelmä rekombinanttisen, liukoisen tyypin I komplementtireseptorimolekyylin puhdistamiseksi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI904842A FI106316B (fi) 1988-04-01 1990-10-01 Ihmisen C3b/C4b-reseptori (CR1)

Country Status (14)

Country Link
EP (1) EP0411031B1 (fi)
JP (1) JP3484189B2 (fi)
CN (2) CN1092712C (fi)
AT (1) ATE240973T1 (fi)
CA (2) CA1340866C (fi)
DE (1) DE68929466T2 (fi)
DK (1) DK175699B1 (fi)
ES (1) ES2014593A6 (fi)
FI (2) FI106316B (fi)
IL (1) IL89790A (fi)
NO (1) NO315944B1 (fi)
SG (1) SG52789A1 (fi)
WO (1) WO1989009220A1 (fi)
ZA (2) ZA892397B (fi)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426029A (en) * 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US6482404B1 (en) 1989-10-12 2002-11-19 David James White Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
ES2060561T3 (es) 1989-10-12 1996-08-01 Imutran Ltd Material biologico modificado.
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) * 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
JP4236698B2 (ja) * 1990-11-26 2009-03-11 ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー 宿主細胞でのｐａｃｅの発現およびその使用法
CA2097825A1 (en) * 1990-12-06 1992-06-07 Henry C. Marsh, Jr. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
EP1413587A2 (en) * 1991-05-03 2004-04-28 Washington University Modified complement system regulator
DE69328098T2 (de) * 1992-06-24 2000-08-24 Adprotech Plc Lösliche derivate des complement type-rezeptors (cr1)
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
ATE223230T1 (de) * 1993-02-12 2002-09-15 Avant Immunotherapeutics Inc Pulmonäre verabreichung des löslichen komplement- receptors typ 1 scr1
BR9708387A (pt) 1996-03-28 2000-01-04 Genitrix Llc Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
GB9706950D0 (en) * 1997-04-05 1997-05-21 Chernajovsky Yuti Immune modulation by polypeptides related to CR1
AU5317499A (en) * 1998-07-24 2000-02-14 Uab Research Foundation Genetic polymorphism in a complement receptor
US6664052B1 (en) 1998-07-24 2003-12-16 The Uab Research Foundation Genetic polymorphism in a complement receptor
GB9905503D0 (en) 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
EP1738763A1 (en) 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Use of complement inhibitory proteins to treat spinal cord injury
US8703136B2 (en) 2006-10-10 2014-04-22 Regenesance B.V. Complement inhibition for improved nerve regeneration
WO2010047793A2 (en) 2008-10-21 2010-04-29 The General Hospital Corporation Cell transplantation
US10184110B2 (en) 2010-08-06 2019-01-22 The General Hospital Corporation System and apparatus for cell treatment
CN103237557A (zh) 2010-09-15 2013-08-07 赛尔戴克斯治疗公司 用可溶性I型补体受体(sCR1)治疗慢性肾病
BR112013010098A2 (pt) 2010-10-27 2017-06-13 Celldex Therapeutics Inc método para melhorar a função de transplante usando um receptor do complemento solúvel tipo i (scr1)
EP3095876A1 (en) 2010-11-02 2016-11-23 Kypha, Inc. Point of care lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders
CN102702339B (zh) * 2011-05-24 2013-10-30 华南师范大学 斜带石斑鱼补体c3基因、载体、重组菌株和蛋白及其应用
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN104293836A (zh) * 2014-06-24 2015-01-21 长沙赢润生物技术有限公司 一种免疫复合物吸附细胞的制作方法
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
EP3760645A1 (en) * 2019-07-02 2021-01-06 imusyn GmbH & Co. KG Analysis for blood group antigen dacy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60192948A (ja) * 1984-03-14 1985-10-01 Fuji Photo Film Co Ltd 湿し水不要ネガ型感光性平版印刷版および製版方法
US4672044A (en) * 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)

Also Published As

Publication number Publication date
JP3484189B2 (ja) 2004-01-06
IL89790A (en) 2002-05-23
SG52789A1 (en) 1998-09-28
WO1989009220A1 (en) 1989-10-05
CN1036987A (zh) 1989-11-08
NO20000827D0 (no) 2000-02-18
NO20000827L (no) 1990-11-09
AU3539489A (en) 1989-10-16
IL89790A0 (en) 1989-09-28
ZA907693B (en) 1992-05-27
CN1053924C (zh) 2000-06-28
CN1053265A (zh) 1991-07-24
CN1092712C (zh) 2002-10-16
ZA892397B (en) 1989-11-29
DE68929466D1 (de) 2003-06-26
ES2014593A6 (es) 1990-07-16
NO315944B1 (no) 2003-11-17
EP0411031A1 (en) 1991-02-06
DK234890A (da) 1990-11-30
DE68929466T2 (de) 2004-04-01
EP0411031A4 (en) 1992-02-05
ATE240973T1 (de) 2003-06-15
CA1340866C (en) 1999-12-28
DK234890D0 (da) 1990-09-28
DK175699B1 (da) 2005-01-24
FI904842A0 (fi) 1990-10-01
AU647371B2 (en) 1994-03-24
FI115528B (fi) 2005-05-31
CA1341443C (en) 2003-10-07
JPH04501502A (ja) 1992-03-19
EP0411031B1 (en) 2003-05-21
FI106316B (fi) 2001-01-15

Similar Documents

Publication Publication Date Title
ATE256181T1 (de) Menschlicher c3b/c4b-rezeptor (cr1)
ATE240973T1 (de) Menschlicher rezeptor c3b/c4b (cr1)
US5401651A (en) DNA encoding ENA-78, a neutrophil activating factor
KR970705405A (ko) 사람 케모킨 폴리펩타이드(Human Chemokine Polypeptides)
BR9809914A (pt) Genes de moracella receptores de lactoferrina
NZ503235A (en) Amino-terminally truncated RANTES as chemokine antagonists
MX9203654A (es) Purificacion, clonacion y caracterizacion del gen para la interleucina i.
JPH05503512A (ja) 白血球接着阻害因子としての［ａｌａ　ｉｌ―８］↓７↓７
KR970705635A (ko) 사람 케모킨 베타-9(Human chemokine beta-9)
PT98695A (pt) Gene codificador do factor neurotrofico de ligacao a heparina
RU2214273C2 (ru) ДНК-ПОСЛЕДОВАТЕЛЬНОСТИ, КОДИРУЮЩИЕ ЧЕЛОВЕЧЕСКИЕ ПРОТЕИНЫ Tx И Ty, РОДСТВЕННЫЕ КОНВЕРГИРУЮЩЕМУ ИНТЕРЛЕЙКИН-1-β ФЕРМЕНТУ
PT83939B (pt) Metodo para a producao de factor angiogenico da placenta humana capaz de estimular a sintese de proteases, sintese de dna e migracao de celulas endoteliais capilares
EP0913470A3 (en) The human C3b/C4b receptor (CR1)
DK595187A (da) Minactivin og fremgangsmaade til fremstilling deraf
KR930701475A (ko) 사람의 거핵구-집락 촉진 인자(hMeg-CSF) 및 그것의 생산방법
BR0208140A (pt) Polipeptìdeo, agente imunoterapêutico para o tratamento de psorìase, sequência de ácido nucléico isolada ou seu complemento, vetores de filamento único, e de filamento duplo, sequência de ácido nucléico isolada ou variante imunogênica da mesma, métodos para a produção de polipeptìdeos, e para o tratamento e a remissão clìnica de psorìase, e, célula hospedeira microbiana

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 115528

Country of ref document: FI